Literature DB >> 12089311

Fatal Saccharomyces cerevisiae aortic graft infection.

Davey Smith1, David Metzgar, Christopher Wills, Joshua Fierer.   

Abstract

Saccharomyces cerevisiae is a yeast commonly used in baking and a frequent colonizer of human mucosal surfaces. It is considered relatively nonpathogenic in immunocompetent adults (J. N. Aucott, J. Fayan, H. Grossnicklas, A. Morrissey, M. M. Lederman, and R. A. Salata, Rev. Infect. Dis. 12:406-411, 1990). We present a case of S. cerevisiae fungemia and aortic graft infection in an immunocompetent adult. This is the first reported case of S. cerevisiae fungemia where the identity of the pathogen was confirmed by rRNA sequencing.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12089311      PMCID： PMC120603          DOI： 10.1128/JCM.40.7.2691-2692.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii.

Authors:  M Niault; F Thomas; J Prost; F H Ansari; P Kalfon
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Saccharomyces cerevisiae empyema in a patient with esophago-pleural fistula complicating variceal sclerotherapy.

Authors:  G M Chertow; E R Marcantonio; R G Wells
Journal:  Chest       Date:  1991-06       Impact factor: 9.410

3.  Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii.

Authors:  S Bassetti; R Frei; W Zimmerli
Journal:  Am J Med       Date:  1998-07       Impact factor: 4.965

4.  Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy.

Authors:  I Fredenucci; M Chomarat; C Boucaud; J P Flandrois
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

Review 5.  Invasive infection with Saccharomyces cerevisiae: report of three cases and review.

Authors:  J N Aucott; J Fayen; H Grossnicklas; A Morrissey; M M Lederman; R A Salata
Journal:  Rev Infect Dis       Date:  1990 May-Jun

6.  Observation of Saccharomyces cerevisiae in blood of patient undergoing root canal treatment.

Authors:  G J Debelian; I Olsen; L Tronstad
Journal:  Int Endod J       Date:  1997-09       Impact factor: 5.264

7.  Fungemia with Saccharomyces cerevisiae in two newborns, only one of whom had been treated with ultra-levura.

Authors:  J Perapoch; A M Planes; A Querol; V López; I Martínez-Bendayán; R Tormo; F Fernández; G Peguero; S Salcedo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-06       Impact factor: 3.267

8.  Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.).

Authors:  M J McCullough; K V Clemons; J H McCusker; D A Stevens
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

9.  Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

Authors:  F Barchiesi; A L Colombo; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948
  9 in total
  10 in total

1.  Genome-wide association analysis of clinical vs. nonclinical origin provides insights into Saccharomyces cerevisiae pathogenesis.

Authors:  L A H Muller; J E Lucas; D R Georgianna; J H McCusker
Journal:  Mol Ecol       Date:  2011-08-31       Impact factor: 6.185

2.  Recombinant form of human wild type mannan-binding lectin (MBL/A) but not its structural variant (MBL/C) promotes phagocytosis of zymosan by activating complement.

Authors:  Rema Rajagopalan; Takazvida Nyaundi; Veena P Salvi; Nenoo Rawal
Journal:  Mol Immunol       Date:  2010-06-25       Impact factor: 4.407

3.  Microsatellite analysis of genetic diversity among clinical and nonclinical Saccharomyces cerevisiae isolates suggests heterozygote advantage in clinical environments.

Authors:  Ludo A H Muller; John H McCusker
Journal:  Mol Ecol       Date:  2009-05-20       Impact factor: 6.185

4.  Comparative genomic analysis reveals a critical role of de novo nucleotide biosynthesis for Saccharomyces cerevisiae virulence.

Authors:  Roberto Pérez-Torrado; Silvia Llopis; Benedetta Perrone; Rocío Gómez-Pastor; Bernhard Hube; Amparo Querol
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

5.  Transcriptomics in human blood incubation reveals the importance of oxidative stress response in Saccharomyces cerevisiae clinical strains.

Authors:  Silvia Llopis; Amparo Querol; Antje Heyken; Bernhard Hube; Lene Jespersen; M Teresa Fernández-Espinar; Roberto Pérez-Torrado
Journal:  BMC Genomics       Date:  2012-08-23       Impact factor: 3.969

6.  Saccharomyces cerevisiae: population divergence and resistance to oxidative stress in clinical, domesticated and wild isolates.

Authors:  Stephanie Diezmann; Fred S Dietrich
Journal:  PLoS One       Date:  2009-04-24       Impact factor: 3.240

7.  Pathogenic potential of Saccharomyces strains isolated from dietary supplements.

Authors:  Silvia Llopis; Carolina Hernández-Haro; Lucía Monteoliva; Amparo Querol; María Molina; María T Fernández-Espinar
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

8.  Whole Genome Analysis of 132 Clinical Saccharomyces cerevisiae Strains Reveals Extensive Ploidy Variation.

Authors:  Yuan O Zhu; Gavin Sherlock; Dmitri A Petrov
Journal:  G3 (Bethesda)       Date:  2016-08-09       Impact factor: 3.154

Review 9.  Opportunistic Strains of Saccharomyces cerevisiae: A Potential Risk Sold in Food Products.

Authors:  Roberto Pérez-Torrado; Amparo Querol
Journal:  Front Microbiol       Date:  2016-01-08       Impact factor: 5.640

10.  Saccharomyces cerevisiae show low levels of traversal across human endothelial barrier in vitro.

Authors:  Roberto Pérez-Torrado; Amparo Querol
Journal:  F1000Res       Date:  2017-06-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.